Analyst Price Targets — ODTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2026 11:00 am | David Nierengarten | Wedbush | $30.00 | $16.96 | TheFly | Odyssey Therapeutics initiated with an Outperform at Wedbush |
| June 2, 2026 10:09 am | Jeff Jones | Oppenheimer | $40.00 | $16.96 | TheFly | Odyssey Therapeutics initiated with an Outperform at Oppenheimer |
Latest News for ODTX
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey…
Healthcare IPO demand is coming back, but investors are not giving every new listing an easy first-day win. Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI)
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ODTX.
Senate Trading
No Senate trades found for ODTX.
U.S. House Trading
No House trades found for ODTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.